![](https://events.berkeley.edu/live/image/gid/154/width/80/height/80/crop/1/src_region/0,0,280,362/3748_tsukamoto-hidekazu.rev.1692830899.png)
End-stage chronic liver disease manifested by cirrhosis and liver cancer (HCC) claims more than 1.5M lives globally. A mesenchymal liver cell type critical in pathologic progression to cirrhosis to HCC, is hepatic stellate cell (HSC) which functions as a vitamin A-storing pericyte in the normal liver but undergoes myofibroblast (MFB) trans-differentiation to participate in liver fibrogenesis and tumor promotion.